Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press25510.17650/2220-3478-2018-8-3-11-16LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫCirculating tumor DNA as a marker of residual tumor in colon cancerЦиркулирующая в крови опухолевая ДНК как маркер резидуальной болезни при раке толстой кишкиhttps://orcid.org/0000-0001-5615-7806FedyaninM. Yu.ФедянинМ. Ю.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

Михаил Юрьевич Федянин.

115478 Москва, Каширское шоссе, 24

fedianinmu@mail.ruElsnukaevaKh. Kh.-M.ЭльснукаеваХ. Х.-М.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

AlievV. A.АлиевВ. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

AyrapetyanT. S.АйрапетянТ. С.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

PolyakovA. V.ПоляковА. В.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

MorozE. V.МорозЕ. В.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

UymanovV. A.УймановВ. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

BoyarskikhU. A.БоярскихУ. А.
Russian Federation

8 Akad. Lavrentyeva St., Novosibirsk 630090

630090 Новосибирск, проспект Акад. Лаврентьева, 8

KechinA. A.КечинА. А.
Russian Federation

8 Akad. Lavrentyeva St., Novosibirsk 630090

630090 Новосибирск, проспект Акад. Лаврентьева, 8

FilipenkoM. L.ФилипенкоМ. Л.
Russian Federation

8 Akad. Lavrentyeva St., Novosibirsk 630090

630090 Новосибирск, проспект Акад. Лаврентьева, 8

https://orcid.org/0000-0001-9807-2229TjulandinS. А.ТюляндинС. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of SciencesФГБУН Институт химической биологии и фундаментальной медицины Сибирского отделения РАН031120188311160211201802112018Copyright ©; 2018, ABV-pressCopyright ©; 2018, АБВ-пресс2018ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/255

Colon cancer is the 3rd most common malignant neoplasm and the 4th leading cause of mortality from them. The majority of patients are diagnosed at stages II–IV, which indicates the need for markers that can predict disease progression, especially after surgical treatment. Recently, there has been a growing interest in exploring circulating tumor DNA as a marker of residual tumor in colon cancer. In 2018, the N.N. Blokhin National Medical Research Center of Oncology together with the Institute of Chemical Biology and Fundamental Medicine under the coordination of the Center for Strategic Planning and Management of Biomedical Health Risks initiated a research project entitled “Development of an assay for the diagnosis of various malignant tumors and treatment efficacy monitoring based on the analysis of circulating tumor DNA from patient blood”. This article provides a theoretical background for the project and a report on its progress made so far.

На рак толстой кишки приходится 3-е место по заболеваемости злокачественными новообразованиями в мире и 4-е место по смертности от них. При этом в большинстве случаях опухоль диагностируется на II–IV стадиях заболевания, что говорит о необходимости изучения маркеров прогрессирования, особенно после радикального лечения. В связи с этим в последние годы появился интерес к изучению в качестве маркера резидуальной опухоли при раке толстой кишки циркулирующей в крови опухолевой ДНК. В 2018 г. ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» совместно с ФГБУН «Институт химической биологии и фундаментальной медицины Сибирского отделения РАН» при координации ФГБУ «Центр стратегического планирования и управления медико-биологическими рисками здоровью» в рамках экспериментального государственного задания Минздрава России инициировали научно-исследовательскую работу «Разработка тест-системы для диагностики и мониторинга эффективности проводимого лечения злокачественных новообразований различной локализации на основе анализа циркулирующей в крови пациентов опухолевой ДНК». В настоящей статье описываются теоретические предпосылки к инициации данного исследования и сообщается, на каком этапе находится выполнение работы.

colon cancercirculating tumor DNAliquid biopsyprognosisрак толстой кишкициркулирующая в крови опухолевая ДНКжидкостная биопсияпрогнозMalignant tumors in Russia in 2016 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Sta rinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2018. 250 p. (In Russ.).Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 250 с.Gunderson L.L., Jessup J.M., Sargent D.J. et al. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010;28(2):264– 71. PMID: 19949014. DOI: 10.1200/JCO.2009.24.0952.Adam R., Aloia T., Figueras J. et al. LiverMetSurvey: analysis of clinicopathologic factors associated with the efficacy of preoperative chemotherapy in 2,122 patients with colorectal liver metastases. J Clin Oncol 2006;24(18 Suppl):3521.Siravegna G., Mussolin B., Buscarino M. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015;21(7):827. PMID: 26151329. DOI: 10.1038/nm0715-827b.Siravegna G., Mussolin B., Buscarino M. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015;21(7):827. PMID: 26151329. DOI: 10.1038/nm0715-827b.Hamzehzadeh L., Yousefi M., Ghaf- fari S.H. Colorectal cancer screening: a comprehensive review to recent non-invazive methods. Int J Hematol Oncol Stem Cell Res 2017;11(3):250–61. PMID: 28989593.Hamzehzadeh L., Yousefi M., Ghaf- fari S.H. Colorectal cancer screening: a comprehensive review to recent non-invazive methods. Int J Hematol Oncol Stem Cell Res 2017;11(3):250–61. PMID: 28989593.Dickinson B.T., Kisiel J., Ahlquist D.A., Grady W.M. Molecular markers for colorectal cancer screening. Gut 2015;64(9):1485–94. PMID: 25994221. DOI: 10.1136/gutjnl-2014-308075.Spindler K.L.G., Appelt A.L., Pallisgaard N. et al. Cell-free DNA levels in colorectal cancer patients treated with irinotecan, healthy controls, and non-cancer patients with comorbidity. J Clin Oncol 2014; 32(5 Suppl):3559.Pucciarelli S., Enzo M., Agostini M. et al. Cell-free circulating DNA as a promising marker of colorectal cancer detection and progression. J Clin Oncol 2009; 27(15 Suppl):11059.Tie J., Kinde I., Wang Y. et al. Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC). J Clin Oncol 2014;32(5 Suppl):11015.Tie J., Kinde I., Wang Y. et al. Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC). J Clin Oncol 2014;32(5 Suppl):11015.Diehl F., Li M., Dressman D. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005;102:16368–73. PMID: 16258065. DOI: 10.1073/pnas.0507904102.Diehl F., Li M., Dressman D. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005;102:16368–73. PMID: 16258065. DOI: 10.1073/pnas.0507904102.Danese E., Montagnana M., Minicoz- zi A.M. et al. Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers. Clin Chem Lab Med 2010;48(11):1665–8. PMID: 20704532. DOI: 10.1515/CCLM.2010.301.Danese E., Montagnana M., Minicoz- zi A.M. et al. Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers. Clin Chem Lab Med 2010;48(11):1665–8. PMID: 20704532. DOI: 10.1515/CCLM.2010.301.Frattini M., Gallino G., Signoroni S. et al. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett 2008;263:170–81. PMID: 18395974. DOI: 10.1016/j.canlet.2008.03.021.Kopreski M.S., Benko F.A., Borys D.J. et al. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst 2000;92(11):918–23. PMID: 10841827Kopreski M.S., Benko F.A., Borys D.J. et al. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst 2000;92(11):918–23. PMID: 10841827Diehl F., Schmidt K., Choti M.A. et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14(9):985–90.Huang T., Xia L., Xu M. et al. Dynamic monitoring of driver gene mutation profiles in plasma cfDNA using an 85 gene panel for postoperative prognosis in colorectal cancer. J Clin Oncol 2018;36(Suppl):e15536.Huang T., Xia L., Xu M. et al. Dynamic monitoring of driver gene mutation profiles in plasma cfDNA using an 85 gene panel for postoperative prognosis in colorectal cancer. J Clin Oncol 2018;36(Suppl):e15536.Tie J., Wang Y., Kinde I. et al. Circulating tumor DNA (ctDNA) in nonmetastatic colorectal cancer (CRC): potential role as a screening tool. J Clin Oncol 2015; 33(3 Suppl):518.Tie J., Wang Y., Kinde I. et al. Circulating tumor DNA (ctDNA) in nonmetastatic colorectal cancer (CRC): potential role as a screening tool. J Clin Oncol 2015; 33(3 Suppl):518.Tie J., Cohen J., Wang Y. et al. Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC). J Clin Oncol 2018;36(Suppl):3516.Tie J., Cohen J., Wang Y. et al. Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC). J Clin Oncol 2018;36(Suppl):3516.Diehn M., Alizadeh A.A., Adams H.-P. et al. Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA). J Clin Oncol 2017;35(15 Suppl):3591.Diehn M., Alizadeh A.A., Adams H.-P. et al. Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA). J Clin Oncol 2017;35(15 Suppl):3591.Li L., Zhou W., Li C. et al. Analysis of circulating tumor DNA to monitor disease status in colorectal cancer after surgery. J Clin Oncol 2018;36(Suppl):e15583.Li L., Zhou W., Li C. et al. Analysis of circulating tumor DNA to monitor disease status in colorectal cancer after surgery. J Clin Oncol 2018;36(Suppl):e15583.Tie J., Cohen J., Wang Y. et al.The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC). J Clin Oncol 2017:35(Suppl):3521.Tie J., Cohen J., Wang Y. et al.The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC). J Clin Oncol 2017:35(Suppl):3521.Yang L., Wang Y., Shen L. et al. Predicting treatment outcome of rectal cancer patients underwent neoadjuvant chemoradiotherapy by ctDNA: the potential use of ctDNA monitoring as organ-sparing approach. J Clin Oncol 2018;36(Suppl): 3608.Yang L., Wang Y., Shen L. et al. Predicting treatment outcome of rectal cancer patients underwent neoadjuvant chemoradiotherapy by ctDNA: the potential use of ctDNA monitoring as organ-sparing approach. J Clin Oncol 2018;36(Suppl): 3608.Overman M.J., Vauthey J.-N., Aloia T.A. et al. Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence. J Clin Oncol 2017:35(Suppl):3522.Overman M.J., Vauthey J.-N., Aloia T.A. et al. Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence. J Clin Oncol 2017:35(Suppl):3522.Tie J., Wang Y., Springer S. et al. Serial circulating tumor DNA (ctDNA) and recurrence risk in patients (pts) with resectable colorectal liver metastasis (CLM). J Clin Oncol 2016;34(Suppl):e15131.Tie J., Wang Y., Springer S. et al. Serial circulating tumor DNA (ctDNA) and recurrence risk in patients (pts) with resectable colorectal liver metastasis (CLM). J Clin Oncol 2016;34(Suppl):e15131.Murray D., Young G.P., Pedersen S.K. et al. A prospective cohort study in colorectal cancer assessing the relationship between post-surgery detection of methylated BCAT1 or IKZF1 ctDNA and risk for residual disease and survival. J Clin Oncol 2018;36(Suppl):3596.Murray D., Young G.P., Pedersen S.K. et al. A prospective cohort study in colorectal cancer assessing the relationship between post-surgery detection of methylated BCAT1 or IKZF1 ctDNA and risk for residual disease and survival. J Clin Oncol 2018;36(Suppl):3596.Fan G., Zhang K., Yang X. et al. Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review. PLoS One 2017;12(2):e0171991. PMID: 28187169. DOI: 10.1371/journal.pone.0171991.Fan G., Zhang K., Yang X. et al. Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review. PLoS One 2017;12(2):e0171991. PMID: 28187169. DOI: 10.1371/journal.pone.0171991.Tham C., Chew M., Soong R. et al. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. Cancer 2014;120(20):3131–41. PMID: 24925595. DOI: 10.1002/cncr.28802.Tham C., Chew M., Soong R. et al. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. Cancer 2014;120(20):3131–41. PMID: 24925595. DOI: 10.1002/cncr.28802.Leung W.K., To K.F., Man E.P.S. et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 2005;100(10):2274–9. PMID: 16181380. DOI: 10.1111/j.1572-0241.2005.50412.x.Leung W.K., To K.F., Man E.P.S. et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 2005;100(10):2274–9. PMID: 16181380. DOI: 10.1111/j.1572-0241.2005.50412.x.Wallner M., Herbst A., Behrens A. et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res 2006;12(24): 7347–52. PMID: 17189406. DOI: 10.1158/1078-0432.CCR-06-1264.Wallner M., Herbst A., Behrens A. et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res 2006;12(24): 7347–52. PMID: 17189406. DOI: 10.1158/1078-0432.CCR-06-1264.Lin P.-C., Lin J.-K., Lin C.-H. et al. Clinical relevance of plasma DNA methylation in colorectal cancer patients identified by using a genome-wide high-resolution array. Ann Surg Oncol 2015; 3(Suppl):1419–27.Liu Y., Chew M.H., Tham C.K. Methylation of serum SST gene is an independent prognostic marker in colorectal cancer. Am J Cancer Res 2016;6(9):2098–108. PMID: 27725914.Matthaios D., Balgkouranidou I., Karayiannakis A. et al. Methylation status of the APC and RASSF1 a promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer. Oncol Lett 2016;12(1):748–56. PMID: 27347211. DOI: 10.3892/ol.2016.4649.Ryan B.M., Lefort F., McManus R. et al. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. Mol Pathol 2003;56(3):172–9.Lindforss U., Zetterquist H., Papadogiannakis N., Olivecrona H. Persistence of KRAS mutations in plasma after colorectal tumor resection. Anticancer Res 2005;25:657–61.Lindforss U., Zetterquist H., Papadogiannakis N., Olivecrona H. Persistence of KRAS mutations in plasma after colorectal tumor resection. Anticancer Res 2005;25:657–61.Wang J.-Y., Hsieh J.-S., Chang M.-Y. et al. Molecular detection of APC, KRAS, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg 2004;28(7):721– 6. PMID: 15185002. DOI: 10.1007/s00268-004-7366-8.Wang J.-Y., Hsieh J.-S., Chang M.-Y. et al. Molecular detection of APC, KRAS, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg 2004;28(7):721– 6. PMID: 15185002. DOI: 10.1007/s00268-004-7366-8.Tie J., Wang Y., Tomasetti C. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8(346):346ra92. PMID: 27384348. DOI: 10.1126/scitranslmed.aaf6219.Herbst A., Wallner M., Rahmig K. et al. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. Eur J Gastroenterol Hepatol 2009;2(5):565–9. PMID: 19282772. DOI: 10.1097/MEG.0b013e328318ecf2.Herbst A., Wallner M., Rahmig K. et al. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. Eur J Gastroenterol Hepatol 2009;2(5):565–9. PMID: 19282772. DOI: 10.1097/MEG.0b013e328318ecf2.Lee H.S., Hwang S.M., Kim T.S. et al. Circulating methylated septin 9 nucleic acid in the plasma of patients with gastrointestinal cancer in the stomach and colon. Transl Oncol 2013;6(3):290–6. PMID: 23730408.